Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirabrutinib + Idelalisib ± Obinutuzumab in Relapsed/Refractory CLL (Phase 2, Germany)
2015-003909-42Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tirabrutinib, idelalisib and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Complete remission rate at Week 25. Started Jun 2016; status: completed.
02
Drugs
tirabrutinibidelalisibobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2015-003909-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003909-42.